Yippie AI Yay? Re-imagining Bavaria’s Biotech ”System Domdey”

October 2024. The success of the Munich biotech hub lured Bavarian politics and its management arms into self-complacency. However, the wind has changed: Broad availability of artificial Intelligence (AI), cautious investors, competitive biotech hubs outside Bavaria – the old boys’ network became patchy. BioM is going to be re-imagined as cluster development strives to connect to new actors and thinks about alternative investments opportunities, but there are some pitfalls.

B2Bioworld enquired into “System Domdey”, changing relations to Fraunhofer, Technical University Munich, competing with UnternehmerTUM/Venture Lab, risk-averse VCs, or roles of Ludwig-Maximilians-University and Max-Planck-Institutes. Some shortcomings of the biotech ecosystem, a deep look at BioM’s revenues, and its track record. Includes an interview with Ralf Huss, BioM Managing Director since 2023. (updated November 2024)


Reading time: 31 min

Read Now:
1,50 EUR (incl. 7% VAT)



Back to section

masthead | contact | terms & disclaimer | data & privacy | © B2Bioworld 2024